KR102070463B1 - 발현 시스템 - Google Patents

발현 시스템 Download PDF

Info

Publication number
KR102070463B1
KR102070463B1 KR1020137017082A KR20137017082A KR102070463B1 KR 102070463 B1 KR102070463 B1 KR 102070463B1 KR 1020137017082 A KR1020137017082 A KR 1020137017082A KR 20137017082 A KR20137017082 A KR 20137017082A KR 102070463 B1 KR102070463 B1 KR 102070463B1
Authority
KR
South Korea
Prior art keywords
nep
pb1f2
protein
delete delete
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137017082A
Other languages
English (en)
Korean (ko)
Other versions
KR20130132894A (ko
Inventor
알레산드라 비텔리
알프레도 니코시아
리카르도 코르테제
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이. filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Publication of KR20130132894A publication Critical patent/KR20130132894A/ko
Application granted granted Critical
Publication of KR102070463B1 publication Critical patent/KR102070463B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020137017082A 2010-12-30 2011-12-30 발현 시스템 Expired - Fee Related KR102070463B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2010/007995 WO2012089231A1 (en) 2010-12-30 2010-12-30 Paramyxovirus vaccines
EPPCT/EP2010/007995 2010-12-30
PCT/EP2011/074307 WO2012089833A2 (en) 2010-12-30 2011-12-30 Expression Systems

Publications (2)

Publication Number Publication Date
KR20130132894A KR20130132894A (ko) 2013-12-05
KR102070463B1 true KR102070463B1 (ko) 2020-01-29

Family

ID=45464575

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137017082A Expired - Fee Related KR102070463B1 (ko) 2010-12-30 2011-12-30 발현 시스템

Country Status (23)

Country Link
US (4) US20140141042A1 (enExample)
EP (2) EP2658573B1 (enExample)
JP (2) JP6324725B2 (enExample)
KR (1) KR102070463B1 (enExample)
CN (1) CN103442731B (enExample)
AU (2) AU2011351380A1 (enExample)
BR (1) BR112013016823A2 (enExample)
CA (1) CA2821111A1 (enExample)
CY (1) CY1124146T1 (enExample)
DK (1) DK2658573T3 (enExample)
ES (1) ES2869199T3 (enExample)
HR (1) HRP20210750T1 (enExample)
HU (1) HUE053986T2 (enExample)
IL (1) IL226551B (enExample)
LT (1) LT2658573T (enExample)
MX (1) MX352205B (enExample)
NZ (1) NZ610743A (enExample)
PL (1) PL2658573T3 (enExample)
PT (1) PT2658573T (enExample)
RU (1) RU2609645C2 (enExample)
SG (2) SG190919A1 (enExample)
SI (1) SI2658573T1 (enExample)
WO (2) WO2012089231A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2869841T3 (pl) 2012-07-05 2022-01-24 Glaxosmithkline Biologicals Sa Nowe schematy prime-boost wykorzystujące polipeptydy immunogenne kodowane przez polinukleotydy
BR112015002131B1 (pt) 2012-08-01 2022-11-01 Bavarian Nordic A/S Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
UA123385C2 (uk) * 2012-08-01 2021-03-31 Баваріан Нордік А/С Рекомбінантний модифікований вірус вісповакцини анкара (mva) та спосіб лікування або попередження інфекцій вірусу rsv
WO2014024026A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
US10016496B2 (en) * 2013-02-01 2018-07-10 Medimmune, Llc Respiratory syncytial virus F protein epitopes
US20140286981A1 (en) * 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
EP3653701A1 (en) 2013-03-15 2020-05-20 The Research Foundation for The State University of New York Attenuated influenza viruses and vaccines
KR20160040290A (ko) 2013-08-05 2016-04-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 면역원성 조성물
CA2951430A1 (en) * 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
JP6983665B2 (ja) 2015-06-12 2021-12-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アデノウイルスポリヌクレオチド及びポリペプチド
MA47016A (fr) * 2015-10-22 2018-08-29 Modernatx Inc Vaccins contre les virus respiratoires
GB201614485D0 (en) 2016-08-25 2016-10-12 Univ Oxford Innovation Ltd Immunogenic composition
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
CA3045976A1 (en) 2016-12-09 2018-06-14 Glaxosmithkline Biologicals Sa Chimpanzee adenovirus constructs with lyssavirus antigens
GB201701239D0 (en) 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
CN107119064A (zh) * 2017-02-21 2017-09-01 南京农业大学 重组枯草芽孢杆菌串联表达禽流感病毒ha抗原片段和pb1－f2蛋白
EP3697902A1 (en) 2017-10-16 2020-08-26 GlaxoSmithKline Biologicals S.A. Enhanced promoter
ES3056141T3 (en) 2017-10-16 2026-02-18 Glaxosmithkline Biologicals Sa Simian adenoviral vectors with two expression cassettes
BR112020007008A2 (pt) 2017-10-16 2020-11-17 Glaxosmithkline Biologicals S.A. vetores adenovirais com dois cassetes de expressão codificando proteínas antigênicas do rsv ou fragmentos das mesmas
SG11202003609VA (en) * 2017-10-25 2020-05-28 Nouscom Ag Eukaryotic cell line
CA3085975A1 (en) 2017-12-20 2019-06-27 Glaxosmithkline Biologicals Sa Epstein-barr virus antigen constructs
BR112020024285A2 (pt) 2018-06-12 2021-03-02 Glaxosmithkline Biologicals S.A. polinucleotídeos e polipeptídeos de adenovírus
CA3106400A1 (en) 2018-07-13 2020-01-16 University Of Georgia Research Foundation Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof
CN109180820B (zh) * 2018-09-19 2021-06-25 天康生物制药有限公司 马流感病毒h3n8亚型的融合蛋白及其制备方法、应用和疫苗
WO2020061443A2 (en) * 2018-09-21 2020-03-26 Board Of Regents Of The University Of Nebraska Methods of making and using universal centralized influenza vaccine genes
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
CN112220921B (zh) * 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100040650A1 (en) * 2008-05-30 2010-02-18 Crowe Jr James E Virus-Like paramyxovirus particles and vaccines

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135312B2 (en) * 1993-04-15 2006-11-14 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
US7655774B2 (en) 2000-02-18 2010-02-02 University Of Washington Ancestral and COT viral sequences, proteins and immunogenic compositions
CN100333792C (zh) 2001-09-28 2007-08-29 南佛罗里达大学 Rsv基因表达疫苗
HU230364B1 (hu) * 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
CA2743750A1 (en) * 2002-02-21 2003-09-04 Medimmune, Llc Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from respiratory syncytial virus
AU2003256823B9 (en) * 2002-07-25 2009-01-08 Medimmune, Llc Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
US7566458B2 (en) * 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
DK1711518T3 (da) 2004-01-23 2010-04-06 Angeletti P Ist Richerche Bio Vaccinebærere for chimpanse-adenovirus
WO2007126887A2 (en) * 2006-03-27 2007-11-08 The Government Of The United States Of America Immunogenic compositions comprising polynucleotides encoding matrix protein 2 and methods of use
WO2008054540A2 (en) * 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
JP6199533B2 (ja) * 2006-07-13 2017-09-20 インスティチュート フォー アドバンスド スタディ ウイルス阻害性ヌクレオチド配列およびワクチン
WO2008028759A1 (de) 2006-09-05 2008-03-13 BSH Bosch und Siemens Hausgeräte GmbH Bodendüse für hartböden
US8772256B2 (en) * 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
JP2011521985A (ja) * 2008-06-03 2011-07-28 オカイロス アーゲー Ｈｃｖ感染の予防および治療のためのワクチン
CA2730737A1 (en) * 2008-07-15 2010-01-21 Novartis Ag Immunogenic amphipathic peptide compositions
WO2010077717A1 (en) * 2008-12-09 2010-07-08 Novavax, Inc. Modified rsv f proteins and methods of their use
WO2010077712A1 (en) * 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
AU2010209938A1 (en) 2009-02-02 2011-08-25 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100040650A1 (en) * 2008-05-30 2010-02-18 Crowe Jr James E Virus-Like paramyxovirus particles and vaccines

Also Published As

Publication number Publication date
HRP20210750T1 (hr) 2021-11-12
IL226551B (en) 2018-04-30
ES2869199T3 (es) 2021-10-25
CN103442731A (zh) 2013-12-11
US11701422B2 (en) 2023-07-18
AU2017203189B2 (en) 2019-06-27
US20240075125A1 (en) 2024-03-07
BR112013016823A2 (pt) 2017-06-13
EP2658573A2 (en) 2013-11-06
CY1124146T1 (el) 2022-05-27
WO2012089833A2 (en) 2012-07-05
DK2658573T3 (da) 2021-05-10
MX352205B (es) 2017-11-13
CA2821111A1 (en) 2012-07-05
JP2017079787A (ja) 2017-05-18
HUE053986T2 (hu) 2021-08-30
US20140141042A1 (en) 2014-05-22
NZ610743A (en) 2015-07-31
EP3868397A1 (en) 2021-08-25
WO2012089231A1 (en) 2012-07-05
RU2609645C2 (ru) 2017-02-02
EP2658573B1 (en) 2021-02-24
RU2013135498A (ru) 2015-02-10
AU2017203189A1 (en) 2017-07-20
SG190919A1 (en) 2013-07-31
WO2012089833A3 (en) 2012-09-13
CN103442731B (zh) 2018-02-27
AU2011351380A1 (en) 2013-06-06
US20170049879A1 (en) 2017-02-23
PT2658573T (pt) 2021-05-21
PL2658573T3 (pl) 2021-08-16
SI2658573T1 (sl) 2021-06-30
JP6324725B2 (ja) 2018-05-16
US20200360509A1 (en) 2020-11-19
SG10201510760WA (en) 2016-01-28
KR20130132894A (ko) 2013-12-05
LT2658573T (lt) 2021-05-25
MX2013007716A (es) 2013-08-09
JP2014504500A (ja) 2014-02-24

Similar Documents

Publication Publication Date Title
KR102070463B1 (ko) 발현 시스템
US20240091338A1 (en) Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
JP2019141062A (ja) インフルエンザウイルスワクチン及びその使用
EP2670430B1 (en) Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses
EP0620277A1 (en) Nucleic acid pharmaceuticals
WO2008156778A9 (en) Influenza m2 protein mutant viruses as live influenza attenuated vaccines
CN117098551A (zh) 编码截短的ns1蛋白和sars-cov受体结合域的流感病毒
JP2023539713A (ja) ワクチン組成物、それらの方法、および使用
JP2024537250A (ja) インフルエンザワクチン
HK40059786A (en) Expression system
EP2869841B1 (en) Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
KR20250153796A (ko) 다중시스트론 백신 및 이의 제조 방법 및 사용 방법
CA3054584A1 (en) Influenza b virus mutants and uses therefor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250121

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250121

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250121